Candriam SCA’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Candriam SCA’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-280,008	Closed	-$9.46M	–	937
2021 Q2	$9.46M	Sell	280,008 -131,507	-32%	-$3.35M	0.06%	292
2021 Q1	$11.4M	Buy	411,515 +3	+0%	+$91	0.09%	231
2020 Q4	$11.9M	Buy	411,512 +22,192	+6%	+$559K	0.09%	235
2020 Q3	$7.89M	Sell	389,320 -5,332	-1%	-$130K	0.07%	270
2020 Q2	$11.9M	Buy	394,652 +270,868	+219%	+$9.76M	0.13%	190
2020 Q1	$5.7M	Buy	123,784 +10	+0%	+$348	0.06%	314
2019 Q4	$5.83M	Buy	+123,774	New	+$3.57M	0.06%	320

Candriam SCA's CNST Position: Q3 2021 in Review

Candriam SCA sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 280,008 shares — an estimated $9.46M sold.

Candriam SCA first reported a position in CNST in Q4 2019 and held it in 7 quarters. The position peaked at $11.9M in Q2 2020. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

Candriam SCA reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Candriam SCA sold 280,008 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $9.46M.
Candriam SCA first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 7 quarters.
Candriam SCA's Constellation Pharmaceuticals, Inc. position peaked at $11.9M in Q2 2020.
0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.